Unlock AI-driven, actionable R&D insights for your next breakthrough.

Croscarmellose Sodium In Tablets: Comprehensive Analysis Of Disintegration Mechanisms, Formulation Strategies, And Advanced Applications

NOV 17, 202658 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Croscarmellose Sodium (CCS), a cross-linked derivative of carboxymethylcellulose sodium, serves as a critical superdisintegrant in modern tablet formulations, enabling rapid disintegration and enhanced bioavailability across diverse therapeutic categories. Its unique swelling mechanism, driven by water uptake and capillary action, distinguishes it from conventional disintegrants and positions it as an indispensable excipient for immediate-release, orodispersible, and suspension tablet systems. This article provides an in-depth examination of CCS's molecular structure, physicochemical properties, formulation optimization strategies, and emerging applications, supported by quantitative data from patent literature and pharmaceutical development case studies.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Structure And Physicochemical Properties Of Croscarmellose Sodium In Tablet Formulations

Croscarmellose Sodium is synthesized through intramolecular cross-linking of sodium carboxymethylcellulose (NaCMC) with a degree of substitution (DS) typically ranging from 0.60 to 0.85 8. The cross-linking reaction, catalyzed by sulfuric acid in aqueous organic solvents (e.g., ethanol-water mixtures at volume ratios of 10:1), proceeds in two stages: initial activation at 40–50°C for 0.5–2.0 hours, followed by cross-linking at 65–75°C for 2.0–4.0 hours 8. This controlled process yields a three-dimensional polymer network with carboxymethyl ether groups (-OCH₂COONa) distributed along the cellulose backbone, creating hydrophilic sites that drive rapid water absorption.

The resulting CCS exhibits a particle size distribution optimized for tableting, with commercial grades (e.g., Ac-Di-Sol®) typically ranging from 30 to 300 μm 13. Key physicochemical parameters include:

  • Degree of Substitution (DS): 0.60–0.85, balancing solubility and swelling capacity 8
  • Moisture Content: ≤10% (w/w), critical for storage stability and preventing premature hydration
  • pH (1% aqueous dispersion): 5.0–7.0, ensuring compatibility with acid-labile or base-sensitive APIs
  • Swelling Index: 4–8 mL/g in water, significantly exceeding that of unmodified starch (2–3 mL/g)

The cross-linked structure prevents dissolution while enabling rapid volumetric expansion upon contact with aqueous media. When incorporated into tablets at 1–10% (w/w) 6, CCS particles swell to 4–8 times their original volume within seconds, generating localized disruptive forces that fragment the tablet matrix through a combination of swelling pressure (estimated at 0.5–2.0 MPa based on confined swelling studies) and wicking action along capillary channels.

Disintegration Mechanisms And Kinetic Performance In Compressed Tablets

The superdisintegrant efficacy of Croscarmellose Sodium derives from three synergistic mechanisms that operate on sub-minute timescales in physiological fluids:

Rapid Water Uptake And Volumetric Swelling

Upon immersion in dissolution media (e.g., 0.02N HCl at 37°C, simulating gastric conditions), CCS particles absorb water at rates exceeding 200% (w/w) within the first 10 seconds 10. This rapid hydration is driven by the osmotic gradient established by ionized carboxylate groups (-COO⁻Na⁺), which attract water molecules into the polymer network. The swelling kinetics follow a pseudo-first-order model, with half-maximal swelling (t₅₀) typically achieved in 5–15 seconds depending on particle size and compression force.

Capillary Action And Wicking

The fibrous morphology of CCS creates an extensive network of micro-channels (1–10 μm diameter) within the tablet matrix. These channels facilitate rapid penetration of dissolution medium into the tablet core via capillary action, described by the Washburn equation: L = (γrcosθt / 2η)^(1/2), where L is penetration depth, γ is surface tension, r is capillary radius, θ is contact angle, and η is viscosity. For CCS-containing tablets, contact angles typically range from 20° to 40°, indicating strong hydrophilicity and efficient wicking 2.

Disruptive Swelling Pressure

As CCS particles expand, they exert radial pressure on surrounding excipients and API particles, mechanically disrupting inter-particulate bonds formed during compression. Finite element modeling suggests localized stress concentrations of 1–3 MPa at CCS-excipient interfaces, sufficient to overcome typical tablet tensile strengths (0.5–2.0 MPa). This mechanism is particularly effective when CCS is distributed both intragranularly and extragranularly, creating a dual-phase disintegration system 4.

Quantitative Performance Data:

  • Disintegration Time: Tablets containing 7% (w/w) CCS disintegrate in approximately 20 seconds in oral cavity conditions (37°C, minimal agitation) 13
  • Dissolution Rate: Formulations with 3.5–8% CCS achieve ≥65% API dissolution within 10 minutes in 1000 mL of 0.02N HCl at 100 rpm 10, 14
  • Comparative Efficacy: CCS outperforms crospovidone and sodium starch glycolate in suspension tablet applications, where the latter develops undesirable ropy consistency 4

Formulation Design Principles For Croscarmellose Sodium In Tablet Systems

Optimizing CCS incorporation requires careful consideration of concentration, distribution strategy, and interactions with co-excipients to balance disintegration speed, mechanical strength, and manufacturing processability.

Concentration Optimization And Dual-Phase Distribution

The optimal CCS concentration typically ranges from 2% to 8% (w/w) of the total tablet weight 2, 6, 13, with higher levels (up to 10%) employed for challenging formulations containing high-dose APIs or hydrophobic actives 9. Exceeding 10% CCS can compromise tablet hardness (reducing from 17–21 SCU to <12 SCU) and increase friability (>1.0%), while levels below 2% yield insufficient disintegration rates (>60 seconds) 3.

Dual-Phase Distribution Strategy:

Distributing CCS between intragranular (within granules) and extragranular (outside granules) phases enhances disintegration efficiency through complementary mechanisms 4, 6:

  • Intragranular CCS (5–10% of total CCS): Incorporated during wet granulation, coating API particles and promoting rapid granule breakdown from within
  • Extragranular CCS (5–10% of total CCS): Added during final blending, facilitating immediate surface wetting and initiating disintegration upon contact with dissolution medium

A 50:50 intragranular:extragranular distribution achieves disintegration times of ~20 seconds, whereas 25:75 or 75:25 ratios result in times exceeding 40 seconds 13. This phenomenon reflects the need for simultaneous surface and core disintegration to prevent formation of a hydrated gel layer that impedes water penetration.

Synergistic Excipient Combinations

Microcrystalline Cellulose (MCC): Co-processing CCS with MCC (10–50% w/w) provides compressibility and structural integrity while maintaining rapid disintegration 2, 4. The optimal MCC grade is Avicel PH-101 (50 μm mean particle size), which forms a porous matrix that accommodates CCS swelling without excessive hardness increase.

Mannitol: In orodispersible formulations, mannitol (55–70% w/w, particle size 30–300 μm) serves as a rapidly dissolving diluent with pleasant mouthfeel 13. Its crystalline structure provides adequate hardness (15–20 SCU) while dissolving quickly to expose CCS particles.

Sodium Lauryl Sulfate (SLS): Adding 50–100% (w/w) SLS relative to CCS content (e.g., 0.5–1.0% SLS with 1% CCS) mitigates disintegration time prolongation during accelerated stability testing (40°C/75% RH) 3. SLS reduces interfacial tension, enhancing water penetration and preventing age-related hardening.

Alginate Complexes: Co-processed additives containing 75–95% MCC and 5–25% calcium-sodium alginate complex (10–50% w/w of formulation) improve suspendibility in water, critical for pediatric and geriatric suspension tablets 2, 4.

Processing Considerations And Granulation Techniques

Wet Granulation with CCS Slurry:

A preferred method involves preparing a 2–15% (w/w) CCS aqueous slurry and using it as the granulating fluid for the API and primary excipients 4. Key parameters include:

  • Slurry Concentration: 5–12% CCS relative to API weight, limiting water to the minimum required for granulation
  • Mixing Time: <10 minutes from slurry preparation to granulation completion, preventing CCS dissolution and loss of disintegrant function
  • Drying Conditions: Fluid bed drying at 50–70°C until moisture content <3% (w/w), preserving CCS structure

Direct Compression:

For moisture-sensitive APIs, CCS can be blended directly with other excipients. This approach requires:

  • Particle Size Matching: CCS and API particles should have similar size distributions (D₅₀ within 50 μm) to prevent segregation
  • Low Shear Mixing: Tumble blending for 10–20 minutes at 15–25 rpm to avoid CCS particle attrition
  • Compression Force Control: Maintaining peak compression forces <15 kN to prevent CCS particle deformation and loss of swelling capacity

Advanced Applications Of Croscarmellose Sodium In Specialized Tablet Formulations

Orodispersible Tablets (ODTs) For Rapid Onset Therapies

Croscarmellose Sodium is the disintegrant of choice for ODTs designed to disintegrate in <30 seconds without water 5, 6, 13. In domperidone ODTs (10 mg dose), a formulation containing 7% CCS, 60% mannitol (160 μm), 2% maltodextrin, and 15% MCC achieves 20-second disintegration with acceptable hardness (12–15 SCU) and friability (<0.8%) 13. The maltodextrin acts as a dry binder, reducing the need for wet granulation and associated moisture exposure.

Taste Masking Integration:

CCS can simultaneously serve as a disintegrant and taste-masking agent when applied as a coating via fluidized bed processing 5, 6. Acetaminophen particles coated with 5–10% CCS (relative to drug weight) using a top-spray configuration (inlet air 60–70°C, spray rate 5–10 g/min) exhibit:

  • Taste Masking Efficacy: 70–85% of panelists report acceptable taste versus 15% for uncoated controls 6
  • Preserved Disintegration: Tablets containing coated particles disintegrate in 25–35 seconds, only 5–15 seconds slower than uncoated formulations
  • Mechanism: The CCS coating rapidly hydrates and swells upon oral contact, forming a transient gel barrier that delays bitter taste perception while still allowing rapid tablet breakdown

Suspension Tablets For Pediatric And Geriatric Populations

Suspension tablets disintegrate within seconds in water to form homogeneous suspensions containing precise API doses, ideal for patients with swallowing difficulties 2, 4. A representative formulation comprises:

  • API: 15–60% (w/w), either water-soluble or insoluble
  • CCS: 2–4% (w/w), providing rapid disintegration
  • MCC: 20–40% (w/w), ensuring suspendibility
  • Alginate Complex: 15–30% (w/w), preventing rapid sedimentation

These tablets achieve complete disintegration in <10 seconds when added to 50–100 mL water, forming suspensions stable for ≥5 minutes (sedimentation rate <2 mm/min) 2.

Extended-Release Formulations With Controlled Disintegration

Paradoxically, CCS can be incorporated into sustained-release systems when combined with pH-modifying agents and hydrophobic polymers 11, 12. In formulations containing:

  • CCS: 3–20% (w/w)
  • Sodium/Potassium Carbonate: 1–20% (w/w), creating localized alkaline microenvironment
  • Magnesium Oxide: 1–20% (w/w), buffering and slowing water penetration
  • Ethyl Cellulose or HPMC: 1–20% (w/w), forming diffusion barriers

The CCS initially swells to create porous channels, but the hydrophobic polymer and alkaline salts modulate water ingress, achieving controlled release over 8–12 hours while maintaining structural integrity against gastrointestinal peristalsis 11, 12. This approach is particularly effective for drugs requiring sustained plasma levels, such as analgesics and antihypertensives.

High-Dose And Poorly Soluble API Formulations

For tablets containing ≥500 mg API or BCS Class II/IV compounds, CCS concentrations of 5–10% (w/w) combined with surfactants enhance dissolution 9. In triphenyl calcilytic tablets (for autosomal dominant hypocalcemia), a formulation with:

  • CCS: 20% (w/w) total (10% intragranular + 10% extragranular)
  • Surfactant (e.g., polysorbate 80): 1–3% (w/w)
  • MCC: 30–40% (w/w)

achieves ≥80% dissolution of the lipophilic API within 30 minutes in pH 6.8 phosphate buffer, compared to <40% for formulations with 5% CCS and no surfactant 9. The surfactant reduces interfacial tension (from ~50 mN/m to ~35 mN/m), facilitating CCS-mediated wetting and dispersion of hydrophobic drug particles.

Analytical Methods For Croscarmellose Sodium Content Determination In Tablets

Accurate quantification of CCS in finished tablets is essential for quality control, particularly in generic formulations where excipient levels must match reference products.

High-Performance Liquid Chromatography With Charged Aerosol Detection (HPLC-CAD)

A validated method employs electrospray HPLC-CAD to detect CCS in complex matrices such as amonavir tablets 1. The procedure involves:

Sample Preparation:

  1. Grind 20 tablets to fine powder (<100 μm)
  2. Accurately weigh powder equivalent to one tablet dose
  3. Extract with 50 mL water:acetonitrile (80:20 v/v) under sonication (15 min, 40 kHz)
  4. Centrifuge at 4000 rpm for 10 minutes, collect supernatant
  5. Filter through 0.45 μm PVDF membrane

Chromatographic Conditions:

  • Column: Amino-bonded silica, 250 mm × 4.6 mm, 5 μm particle size
  • Mobile Phase: Gradient elution from 75% acetonitrile to 50% acetonitrile over 20 minutes
  • Flow Rate: 1.0 mL/min
  • Detection: CAD with nitrogen pressure 35 psi, filter constant 5 seconds
  • Injection Volume: 10 μL

Performance Metrics:

  • Specificity: No interference from other excipients (MCC, lactose, magnesium stearate) or API 1
  • Linearity: R² > 0.999 over 0.5–5.0 mg/mL CCS range
  • Recovery: 98.5–101.2% across low, medium, and high concentration levels 1
  • Precision: RSD < 2.0% for six replicate injections

This method is particularly advantageous as CAD

OrgApplication ScenariosProduct/ProjectTechnical Outcomes
FMC CORPORATIONImmediate-release tablets, orodispersible tablets (ODTs), and suspension tablets requiring rapid disintegration for pediatric and geriatric populations with swallowing difficulties.Ac-Di-SolEnables rapid tablet disintegration within 20 seconds in oral cavity conditions and achieves ≥65% API dissolution within 10 minutes through dual-phase distribution strategy combining swelling pressure and capillary wicking mechanisms.
FMC CORPORATIONOrodispersible formulations of bitter-tasting APIs such as acetaminophen requiring immediate palatability and rapid onset of action without water.Ac-Di-Sol Taste Masking SystemProvides dual functionality as both taste-masking coating (70-85% panelist acceptance) and disintegrant when applied at 5-10% coating level via fluidized bed processing, maintaining tablet disintegration in 25-35 seconds.
AMERICAN HOME PRODUCTS CORPORATIONHigh-dose calcium supplement tablets (≥80% tricalcium phosphate) requiring long-term storage stability and consistent disintegration performance in resource-limited distribution environments.Calcium Supplement TabletsIncorporation of 50-100% sodium lauryl sulfate relative to croscarmellose sodium content prevents disintegration time prolongation during accelerated stability testing (40°C/75% RH) while maintaining tablet hardness of 17-21 SCU.
Shionogi & Co. Ltd.Sustained-release tablets for analgesics and antihypertensives requiring prolonged plasma levels with structural integrity against mechanical stress in the GI tract.Extended Release Formulation SystemCombines 3-20% croscarmellose sodium with sodium/potassium carbonate (1-20%) and hydrophobic polymers (ethyl cellulose/HPMC) to achieve controlled 8-12 hour drug release while creating porous channels and withstanding gastrointestinal peristalsis.
CALCILYTIX THERAPEUTICS INC.High-dose tablets (≥500 mg) and poorly soluble API formulations for autosomal dominant hypocalcemia treatment requiring enhanced bioavailability of hydrophobic therapeutic compounds.Triphenyl Calcilytic TabletsUtilizes 15-25% total croscarmellose sodium (10% intragranular + 10% extragranular) with surfactants (1-3%) to achieve ≥80% dissolution of lipophilic API within 30 minutes for BCS Class II compounds, compared to <40% with conventional formulations.
Reference
  • Method for detecting content of croscarmellose sodium in amonevir tablet
    PatentInactiveCN118032979A
    View detail
  • Pharmaceutical suspension tablet compositions
    PatentInactiveUS5955107A
    View detail
  • Calcium supplement compressed tablets
    PatentInactiveUS4781925A
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png